Reports Q3 revenue $30.2M, consensus $80.39M. The company said, “Highlights include government-funded, reimbursed compassionate access in France for botensilimab plus balstilimab, new survival data presented at ESMO and ESMO-GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- AGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Agenus Inc. Advances Cancer Treatment with Promising Study Update
- Agenus Inc. Advances Cancer Treatment with New Drug Combination Study
- Promising Clinical Trial Results Support Buy Rating for Agenus’s Botensilimab and Balstilimab Therapy
- Agenus announces new data from its BOT/BAL at ESMO 2025